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Abstract
Targeted, especially stratified or biomarker-guided, therapies offer significant advantages over
traditional oncology therapies in certain settings. Selecting patients most likely to respond to a drug
increases the therapeutic efficacy while reducing toxicities and may accelerate regulatory approval since
smaller clinical trials are needed to demonstrate benefit. Several drugs, including vemurafenib and
crizotinib have demonstrated these benefits along with commercial success. However, significant risk
exists for the drug developer since approval may be threatened if they fail to meet unclear and differing
yet parallel requirements for both the drug and the required companion diagnostic. Tumor biology is
also increasingly complex since recent studies suggest that there are limited numbers of individual driver
mutations, complicated interactions throughout signaling pathways as well as extensive tumor
heterogeneity, all of which will challenge the effectiveness of targeted therapies.
Clinical trial strategy decisions can greatly impact the success of a targeted therapy due to these
challenges. While therapeutic efficacy is considered important, biomarker prevalence and companion
diagnostic performance have been shown to be as important, yet more informative at the time
decisions are made. I hypothesized that common prevalence and companion diagnostic performance
thresholds are being used to guide biomarker-guided clinical trial strategy decisions for targeted
oncology therapies. Seventeen interviews with preclinical, clinical or translational leads were conducted
across a focused set of ten "pathway-modifying" cancer drug programs (CDK4/6, MDM2 and P13KP
inhibitors) that reflect the biological complexity of future targeted therapies. These interviews provided
empirical data as to how biomarkers are being incorporated into current clinical trial decisions.
All respondents were planning to use a companion diagnostic for their program, however, the use of
biomarkers varied significantly. For those programs with ongoing clinical trials in phase I and II, 54%
(n=7/13) were pursuing a biomarker-guided strategy while 46% (n=6/13) were using an initial all-comers
strategy. This fairly equal split separated when compared by phase where trials in phase I and 1/11, 60%
(n=6/10) were using an all-comers strategy but for those trials in phase II (n=3), all were using
biomarker-guided strategies. A key finding of the interviews was that 66.7% (n=4/6) were planning
biomarker enrichment as part of expansion plans. Disproving my hypothesis, however, common
thresholds for neither biomarker prevalence nor companion diagnostic performance were being used to
guide these decisions. Biomarker prevalences of 50-100% were stated as potentially appropriate for an
all-comers strategy. Companion diagnostic performance thresholds were even less influential as only a
few respondents provided a general range of desired sensitivity and specificity. This study found that
actions of drug developers are not necessarily following the emerging recommendations for targeted
therapies due to the significant challenges of biomarker and companion diagnostic development.
Thesis Supervisors: Ernst R. Berndt, PhD - MIT Sloan School of Management
Keith T. Flaherty, MD - Massachusetts General Hospital, Harvard Medical School
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1. Introduction
Several successful stratified therapies have emerged over the past decade with the evolution of
"personalized" medicine. Targeted therapies have been developed with many of them being restricted
to populations that were likely to respond using a biomarker. These biomarker-guided therapies
provide substantial advantages over traditional cancer drug development. Therapeutic efficacy can be
improved and the toxicities reduced with a biomarker-selected population and smaller clinical trial sizes
may be needed therefore accelerating the approval timeline with potentially less cost. While a
biomarker-selected population is smaller than the overall market, the improved therapeutic window
and efficacy allows for a dynamic in which adoption can be maximized and administered in a chronic
setting, thereby increasing the commercial value to a desired level. This has led to different clinical trial
designs, which while useful for stratified therapies, are not universally applicable across targeted
therapies and serious consideration needs to be given to choosing between a biomarker-selected
population or leveraging the strengths of a traditional all-comers approach in early stage clinical trials.
Several disadvantages exist for using smaller clinical trials, such as not having a diverse or large enough
patient population to detect responses, toxicities and perhaps even the correct biomarker. The use of a
selection biomarker requires a certain level of validation and that level is yet to be defined, which adds
confusion and possibly impacts the success of the therapeutic. Additionally, to have a drug apply to only
a biomarker-selected population, the patients must be reliably identified by a diagnostic test, which has
its own significant challenges. Recent US Food and Drug Administration (FDA) guidelines are also
recommending that the diagnostic, termed a companion diagnostic, would be approved in parallel with
the drug. These requirements are still evolving and create uncertainty as to not only the technical
specifications of the diagnostic but also how best to incorporate the biomarker development into the
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drug process. Significant risk exists for drug developers of biomarker-guided targeted drugs since there
is a lack of companion diagnostic expertise within most companies and the technology is constantly
evolving. Another critical challenge is that as our knowledge of tumor biology increases, the landscape
for significant drug targets and the ability to inhibit them, similar to those that contributed to the
success of imatinib, vemurafenib and crizotinib, decreases. Reduced molecular aberrations that drive
tumorigenesis, interaction and signaling throughout the biological pathway and tumor heterogeneity all
contribute to this increased biological complexity.
There are a multitude of factors that contribute to the eventual commercial success of a therapy from
the clinical trial assumptions (size, cost, time, etc.), to the probability of technical and regulatory success
(therapeutic efficacy, toxicities, approval, etc.), and the overall market (size, prevalence, share, price,
adoption, etc.). Targeted therapies using a biomarker-guided strategy add factors relating to the
biomarker definition and companion diagnostic performance. However, the factors that are believed to
have the most impact for stratified medicines are therapeutic efficacy, biomarker prevalence, and the
companion diagnostic performance. Unfortunately, when making critical clinical trial decisions, true
therapeutic efficacy is not known due to the biological complexity and lack of representative preclinical
models.
Prevalence and companion diagnostic performance are therefore the key inputs to determine the
clinical trial strategy for a targeted oncology therapy. Through interviews with leads of drug
development programs, in this pilot study I assess the use of and hypothesize that common prevalence
and companion diagnostic thresholds are being used to help guide early-stage biomarker-guided clinical
trial strategy decisions. To evaluate this hypothesis empirically, I examined several molecular targets of
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drugs in development, described here as "pathway-modifying" targeted therapies that illustrate the
challenges of increased biological complexity.
This thesis is organized in the following manner. The Background section will provide an overview of not
only the factors contributing to the success of targeted oncology and stratified therapies but also the
critical challenges they may face that minimize future successes. Targeted therapies will be defined in
terms of mechanisms but also by their use within a biomarker selected patient population. Case studies
of trastuzumab, imatinib, and more recent examples, vemurafenib, and crizotinib, illustrate the benefits
that stratified medicine can have on the development of oncology therapeutics. The challenges
surrounding regulations and scientific biological complexity will also be discussed to provide perspective
on the concerns that threaten future success for targeted therapies. As part of this thesis, drug targets
were chosen to represent the level of biological complexity that is expected to continue for targeted
drug developers. A section provides a scientific overview of these targets to help illustrate how key
findings of scientific investigation are impacted and the potential implications on developing therapies.
The Study Purpose and Methodology section will provide an overview of the resources used in the
course of this study and the particular dataset that was used for qualitative investigation. The interview
guide is also shared to provide a view into the discussions held with interviewees. Relevant interview
responses are discussed and summarized in the Results section. The Discussion section will provide a
summary of the findings and insights on the context and concerns for drug developers. There are
several areas for future research that will be suggested, but the thesis will conclude with a summary of
the analysis and implications for biomarker-guided targeted drug development.
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2. Background
Emergence of Targeted Therapies
Targeted oncology therapies, or "personalized"/"stratified" medicines for those targeted agents being
used in biomarker-selected populations, have grown in prevalence and importance in medical
treatments since the emergence of endocrine receptor positive breast cancer. To illustrate the increase
across therapeutic areas, in 2006 there were only 13 examples of personalized medicine drugs,
treatments and diagnostics products while in 2011 that number grew to 72 (Personalized Medicine
Coalition, 2011). Growth in this area will continue since while only 30% of all treatments in late clinical
development rely on biomarker data, 50% of those in early clinical development and 60% of all
treatments in preclinical development do (Tufts Center for the Study of Drug Development, 2010). The
growth is likely a result of the clinical, regulatory and commercial success of the types of therapies,
especially in oncology indications.
Traditional cancer chemotherapy works by inhibiting cell division through several mechanisms.
Alkylating agents interfere with DNA base pairing which prevents DNA replication, antimetabolites also
prevent DNA replication by blocking the use of essential nucleic acids, while topoisomerase inhibitors
block DNA uncoiling and taxanes and vinca alkaloids interfere with mictotubule function (Gerber, 2008).
Since many normal rapidly dividing cells are also affected by these therapies, significant toxicities can
result. Unfortunately, in addition to the severe side effects patients experience with traditional
chemotherapy, the level of efficacy has been limited. Curative outcomes in patients with advanced
cancers have been restricted to the subpopulations with testicular cancer, leukemia, and lymphoma,
which account for fewer than 10% of all cancer cases (DeVita, 2011). Only a modest life-prolonging or
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palliative benefit has been observed in several more common cancers. Additionally, there is only a 25%
rate of efficacy with standard drug treatment across cancer types (Aspinall, 2007).
Targeted therapies, on the other hand, prevent the proliferation of tumor cells by blocking or interfering
with specific molecules that have been implicated in tumor formation, proliferation, and metastasis.
Often, these molecular mediators are mutated or overexpressed in tumor cells. In theory, increased
efficacy compared to traditional chemotherapy would be anticipated by targeting molecules that are
fundamental in the formation or dissemination of a patient's tumor. Toxicities would also likely be
reduced by targeting molecules and pathways that cancers have "selected" as conferring a growth or
survival advantage, whereas normal tissues take advantage of the redundancy of proliferative and
survival pathways and are less harmed by inhibition of a specific signaling molecule or pathway.
Another benefit to targeted therapies is that with reduced toxicities, treatment options become
available for those that would be unable to tolerate traditional chemotherapy (Gerber, 2008) and they
can be administered over many years in a chronic setting.
Targeted therapies may or may not utilize a biomarker to help identify which patients would most likely
respond to the drug. The term biomarker can be used broadly and includes those markers used to
inform target and pathway modulation and decisions surrounding pharmacokinetics (PK),
pharmacodynamics (PD), and pharmacogenomics. For the purposes of this thesis, the term biomarker is
one that is predictive and used to stratify or select a patient population for those "associated with
response to or lack of response to a particular therapy" (Yap, 2010). Biomarkers also can be
characterized differently as dichotomous or continuous. A dichotomous biomarker is one in which there
is a binary yes or no decision as to whether a patient has a given biomarker. A continuous biomarker is
one where a "cutoff" point for being considered biomarker positive needs to be made. Essentially there
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is a range of biomarker positive and negative testing responses that overlap and represent a potential
continuum of response to any given therapy (see Figure 1 for example).
Figure 1. Continuous biomarker cut-off example (Trusheim, 2011)
e Clinical performance of companion diagnostic
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Some of the most visible early examples of stratified or biomarker-guided targeted cancer therapies
were trastuzumab (Herceptin, Genentech/Roche) for breast cancer in 1998 (a continuous biomarker)
and imatinib (Gleevec, Novartis) (a dichotomous biomarker) for chronic myelogenous leukemia (CML) in
2001 (FDA). In metastatic breast cancer, the overall response rate for Herceptin was 45% as compared
to 29% in the control group and median time to progression increased from 2.7 months with the control
group to 7.2 months with Herceptin for the approximately 25% of breast cancer patients with
overexpression of HER2 (Trusheim, 2011). Imatinib dramatically changed the landscape of CML
treatment by targeting what was found to be the driving mutation in over 90% of patients, the BCR-ABL
gene. The five-year survival rate once imatinib was introduced as a first-line therapy for CML increased
from approximately 50% to 89% (Druker, 2006). Since the emergence of these successes, it has become
clear that targeted therapies have applications in a wide range of cancer types (See Figure 2). Both
companies and patients have been able to benefit from the shift to stratified medicine.
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Figure 2. Frequency of drug targets by indication (Winslow, 2011)
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Benefits of Stratified Medicine in Oncology
Several case studies have demonstrated significant benefits to developing targeted therapeutics using a
stratified patient population strategy. Favorable risk/benefit profiles have been documented across
dozens of therapeutics through limiting the clinical trial patient population to those expected to benefit
from the drug or not experience adverse events. An accelerated approval timeline has also emerged,
especially with the approval of two recent compounds and commercial value has been proven despite
the typically unfavorable smaller applicable patient populations.
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The cases of trastuzumab and imatinib provide clear benefits for efficacy as compared to traditional
chemotherapy as mentioned above. Subsequent targeted therapies also provided improved response
rates as shown in the table below. Trials utilizing these stratified medicines were conducted with
biomarker-guided strategies where patient selection was limited to those having the hypothesized
target aberrations. Limiting the patients to those likely to experience a benefit theoretically increased
the therapeutic efficacy.
Table 1. Examples of early clinical trial response rates (adapted from Dienstmann, 2012)
Marker/Population Agent Mechanism of Action Response
CD117-overexpressed GIST Imatinib c-KIT, PDGFR 54%
inhibitor
BRCA1/2 mutant breast, ovarian and prostate Olaparib PARP inhibitor 47%
cancer
BRAF V600E-mutant melanoma Vemurafenib BRAF inhibitor 75%
Dabrafenib BRAF inhibitor 60%
ALK-rearranged NSCLC Crizotinib ALK, MET inhibitor 57%
Basal cell carcinomas (majority have Vismodegib SMO inhibitor 58%
inactivating mutations in PTCH1 or activation (Hedgehog pathway)
of SMO)
The increased therapeutic efficacy with a biomarker-guided targeted therapy allows for significantly
smaller clinical trials to demonstrate a clinical benefit and accelerates the path to approval.
Vemurafenib (Zelboraf, Roche) and crizotinib (Xalkori, Pfizer) were approved in August 2011 with a
corresponding companion diagnostic (Roche's cobas 4800 BRAF V600 Mutation Test and Abbott's Vysis
ALK Break-Apart FISH Probe Kit, respectively) to reliably identify those patients that would benefit from
the treatment (FDA). Both drugs received accelerated approval under the FDA's priority review program
for those therapies addressing critical unmet needs (Chabner, 2012). Vemurafenib was able to achieve
approval with a single arm phase 11 study and a randomized (but with crossover) phase III trial totaling
807 patients. An early phase I study was able to show an 81% response rate with only 32 patients.
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Clinical development was clearly accelerated as approval was achieved only four years after the first
patient entered the phase I trial. Crizotinib achieved approval in only three years after the first patient
entered the phase I trial. The pivotal trials were an 82 patient expansion cohort of a phase I trial and a
confirmatory phase Il trial with 173 patients for non-small cell lung cancer. These therapies illustrate
that drug development timelines can be shortened by using biomarker-guided clinical trial strategies
where the subpopulation constitutes an unmet need and where smaller sample sizes are required to
show significantly greater therapeutic efficacy over standard therapy.
Further clinical success of targeted therapies over traditional chemotherapy was reflected in regulatory
approvals as well. From 2000 to 2008 only five traditional chemotherapeutic agents were approved as
new anticancer therapies by the FDA while in that same timeframe, 15 targeted therapies were
approved (Gerber, 2008). As of this year, 2012, almost two-dozen targeted therapies (both first in class
and follow-on molecules) have been approved. A breakdown of those therapies, their targets and
indications is listed in the table below.
Table 2. FDA approved targeted therapies for cancer treatment (Li, 2012)
Small molecule inhibitors for cancer
Dasatinib BCR-ABL, SRC family, c-KIT, Chronic myeloid leukemia (CML), acute lymphocyticPDGFR leukemia
Erlotinib EGFR Non-small cell lung cancer(NSCLC), pancreatic cancer
Gefitinib EGFR NSCLC
Imatinib BCR-ABL, c-KIT, PDGFR Acute lymphocytic leukemia, CML, Gastrointestinal
stromal tumor
Lapatinib HER2/neu, EGFR Breast cancer
Sorafenib BRAF, VEGFR, EGFR, PDGFR Renal cell carcinoma(RCC), Hepatocellular carcinoma
Sunitinib VEGFR, PDGFR, c-KIT, FLT3 RCC, gastrointestinal stromal tumor
Temsirolimus mTOR, VEGF RCC
Pazopaniba VEGFR-1, VEGFR-2, VEGFR- RCC
3, PDGFR-a/3, and c-kit
Nilotinib BCR-ABL CML
Crizotinib ALK, HGFR NSCLC
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Vemurafenib BRAF Late-stage melanoma
Monoclonal antibodies for cancer
Alemtuzumab CD52 Chronic lymphocytic leukemia
Bevacizumaba VEGF Colorectal cancer, NSCLC, RCC
Cetuximab EGFR Colorectal cancer, head and neck cancer
Gemtuzumab
ezugamab CD33 Relapsed acute myeloid leukemiaOzogamicin _____________
lbritumomab CD20 Non-Hodgkin's lymphoma (NHL) (with yttrium-90 or
Tiuxetan indium-111)
Panitumumab EGFR Colorectal cancer
Rituximab CD20 NHL
Tositumomab CD20 NHL (with lodine-131)
Trastuzumab HER2/neu Breast cancer with HER2/neu overexpression
Commercial success has also been achieved despite initial concerns that smaller patient populations
would limit revenues. The biomarker prevalence for each therapy varies widely from >90% for BCR-ABL
and imatinib, 40-60% for BRAF and vemurafenib to 4-6% for ALK and crizotinib. Clearly, pre-selecting
patients can severely reduce a potential patient population. However, a number of factors contribute to
each therapy's overall success thereby compensating for the smaller market. As mentioned previously,
by including only those patients likely to respond to the drug through biomarker-selection, smaller
numbers of patients are needed in clinical trials to establish clinical evidence of benefit. The design of
these targeted therapies also allows the drug to be taken chronically, which extends the overall market.
This has led to the concept of patient-years being a better measurement for an oncology market
opportunity. Imatinib is a clear example of this in CML where the drug is administered chronically as a
maintenance therapy for years and not a single administration regimen as in the cases of traditional
chemotherapy. Trastuzumab also utilizes the same principle where patients will typically receive the
drug in combination with multiple lines of other therapies (Flaherty, 2012). The positive risk/benefit
profiles help to drive stronger adoption by physicians and better compliance by patients, but also helped
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to set a new standard for oncologic agent pricing; over $100,000 for a year of treatment (National
Cancer Institute, 2011). An example of this dynamic is illustrated in the figure below.
Figure 3. Factors contributing to commercial value of stratified therapies (Trusheim, 2007)
Empirical
stratified
medic-ine
Patient
$t CCompliance
Market share ()
Imatinib (and its follow-on nilotinib) brings in over five billion in revenue per year (Novartis, 2011). This
represents a clear commercial success for Novartis that initially was applicable to only 9,000 patients
worldwide (Novartis, 2001).
Stratified Medicine Regulatory Environment
Evidence-based medicine and the regulations structured to support it require a novel therapy to prove
superiority (or in many cases non-inferiority) over the current standard of care that ideally is
accomplished through large, prospective, randomized, and multi-centre studies. With the increased
approvals of targeted agents, the FDA has adapted (as seen by the targeted agents discussed previously)
and is attempting to provide stronger guidance on the requirements for drugs being used in smaller
(often orphan) indications and only in molecularly-stratified patients. Last year in July 2011 the FDA
issued its first draft guidance (final issuance date is unknown) for the use of in vitro companion
diagnostic devices (IVD). It was meant for not only the device manufacturers but also those sponsors
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"who are planning to develop a therapeutic product that depends on the use of an in vitro companion
diagnostic device (or test) for its safe and effective use". It recommends that for a novel therapeutic
product, an IVD should be developed and approved "contemporaneously". The FDA plans to ensure
that the IVD is properly validated and meets acceptable safety/efficacy standards before approving the
therapeutic product (FDA, 2011). It is important to note that the regulatory processes for each have
their own nuances and requirements as they are reviewed by two separate branches; Center for Drug
Evaluation and Research (CDRH)/Center for Biologics Evaluation and Research (CBER) for drugs and
Center for Devices and Radiological Health (CDRH) for devices. The most recent approvals of
vemurafenib and crizotinib followed this strategy ensuring that the commercial assay to be used was
validated as part of the clinical trials. Interestingly, this guidance follows the strategy several other
targeted oncology products took as well; Herceptin and its companion diagnostic by Dako achieved joint
approval in 1998, as did Dako with its EGFR pharmDx for Erbitux and Vectibix in 2004 and 2006
respectively (FDA).
In order to comply with these regulations drug makers will need to adopt practices to develop a reliable
method of identifying those patients likely to benefit from the therapeutic during clinical trials and
essentially validate the drug, novel biomarkers and an associated IVD for approval. The significant risks
can be disproportionate with biomarker-guided clinical trials since if the companion diagnostic is not
able to meet its technical or scientific specifications through registration trials, the approval of the drug
is also threatened. Therefore, specific activities related to the companion diagnostic must begin very
early in the clinical trials process to ensure that a reliable assay is available for pivotal trials (potentially
as early as phase 11).
18
Challenges for Stratified Medicine in Oncology
The decision whether to stratify the patient population based on a predictive biomarker remains
challenging despite recent successes of therapies using predictive biomarker based strategies. The
frequent practice of limiting the patient population, especially in early clinical trials has significant
drawbacks. Phase I trials are typically used to ensure safety and find potential doses for the next set of
clinical trials (Yap, 2010). By limiting the patient enrollment it is possible that important off-target
effects, that could mediate efficacy and broader market potential, could be missed. There is also the
possibility that target inhibition could be dose-dependent and by not including a range of patients with
varying target levels potential benefits to a wider patient population could be missed. For example,
expression of proteins is a common biomarker and while high expression may respond at the highest
levels, by not including lower levels of expression responses (as occurred with Herceptin) would not be
detected and developed further. The biological complexity and heterogeneity issues noted above can
contribute to the fact that a target and its biomarker may not be validated to the extent necessary.
With small and restricted patient populations the drug could actually impact other targets or not be the
primary marker of response sensitivity. The success of crizotinib actually began as a MET inhibitor and
only after further investigation was its effect on ALK mutations found. Sorafenib is another example
where it was originally thought to be a targeted inhibitor of RAF but in fact was a potent VEGF2 inhibitor
(Carden, 2010). The complicated EGFR history provides an example of how the true marker can be
missed as well (Janku, 2011). Although developers and regulatory authorities focused on EGFR
mutations, KRAS proved to be the primary (albeit negative) predictor of response to cetuximab and
panitumumab. The subsequent validation of KRAS went so far as to remove EGFR as a biomarker since
the NCCN states in its guidelines "EGFR testing has no demonstrated predictive value, and therefore
routine EGFR testing is not recommended" (National Comprehensive Cancer Network, 2009). These
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primary scientific and clinical challenges directly reflect the biological complexity. Clearly, they can
impact the success of choosing a stratified medicine strategy for a novel anticancer agent.
Additional regulatory and cost challenges still exist despite the FDA's commitment to improving the
process and collaboration to bring biomarker-stratified medicines to the market. There is no consensus
as to how a targeted therapy should be studied in a selected population. The FDA Oncologic Drugs
Advisory Committee initially suggested that therapies should be evaluated in both biomarker-positive
and biomarker-negative populations, which would require extremely large trials and negate the benefit
of smaller, faster and cheaper development for targeted therapies. The therapy that should serve as a
comparator is also unclear as some biomarkers confer a tumor growth advantage (or disadvantage in
terms of clinical outcomes) and may identify a subpopulation of patients who fare poorly with current
standard of care treatments (Schilsky, 2011). The FDA also desires insight regarding the natural history
of the biomarker selected patient populations and not just the response to a therapy. This can be
challenging for companies that do not have access to this type of information or the tumor samples
needed to produce this type of information (Flaherty, 2012). Dr. Hakan Sakul, who was responsible for
the diagnostic associated with crizotinib on the Pfizer side, stated that a key learning from their
experience was to meet with the FDA and CDRH early to understand the diagnostic pathway (Sakul,
2011).
Finding the appropriate patients and the time and cost to do so also adds additional considerations
(Schilsky, 2011). A total of 2107 patients were screened to enroll 675 for vemfuramib's pivotal trial.
Each of those screenings incurred the cost of the diagnostic and added time to identifying those patients
(Roche/Genentech, 2011). A more drastic example is that for crizotinib, Pfizer/Abott screened
approximately 1,500 patients in order to identify the 82 patients enrolled in the phase I clinical trial
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(Kwak, 2010). To make the diagnostic validation and clinical trial process more efficient, recent targeted
therapies have used the drug clinical trials as evidence for both the drug and diagnostic approvals.
While this approach can be efficient, the sponsors and investigators must be diligent to include all
relevant and differing requirements for approvals from separate regulatory agencies (Phillips, 2006).
The success of companion diagnostics associated with approved targeted therapies and the regulatory
requirements around using the therapies in a selected population has likely helped to drive the surge in
drug and diagnostic company co-development deals (PricewaterhouseCoopers, 2011). There are many
challenges to these co-development deals, however, and it may be more prudent to avoid the process
through not limiting or selecting the patient population. The relationship of drug and diagnostic
developers is complicated due to mismatched timelines and incentives. During a discussion at the 2011
Personalized Medicine Conference, Dr. Stafford O'Kelly from Abbott stressed that the two-year timeline
(due to crizotinib's accelerated approval) to develop a commercializable companion diagnostic was
difficult and Pfizer/Abbott were only able to achieve it because there were other sources of data to
support a modular submission. If a companion diagnostic is required, he stressed that an IVD should be
developed as soon as possible and be available for phase 11 studies, which is difficult given the biological
complexity as discussed below (O'Kelly, 2011). In addition to the fact that diagnostics have their own
regulatory and phase I through Ill testing as mentioned previously, the product development cycle of
diagnostic devices is slightly different from that of drugs in that there is typically an iterative process
during which subsequent refinements will be made. For example, HER2 testing has undergone
considerable changes and improvements since its first introduction, with a new test even being
approved this year, more than a decade after its development (FDA). The lack of investment in
diagnostics and the limited reimbursement rates may also make it difficult to attract a diagnostic
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partner and ensure their commitment for something that is absolutely critical to the drug and its
significantly greater commercial value (Phillips, 2006).
Increasing Biological Complexity
Advancements in genomics and other diagnostic technologies have enabled a stronger understanding of
tumor drivers. Unfortunately, recent investigations have shown an Increasing biological complexity that
will be a key consideration for future targeted drug developers. Projects such as The Cancer Genome
Atlas (TCGA) have shown remarkably few genes that are mutated at a high frequency across cancer
indications (Yauch, 2012) suggesting that clear drivers such as BRAF and ALK will be difficult to come by
in the future.
Another key challenge is that not all mutations or aberrations are druggable. Oncogenes relate to
activated molecules that can be targeted and inhibited with drugs. Oncogenes can transform the cells
to drive cellular proliferation. The BRAF V600E mutation and ALK-EML4 fusion are examples of these
types of events (Flaherty, 2012). "Oncogene addiction" is a concept where one or a few genes are
responsible for both the maintenance of the malignant phenotype and cell survival (Weinstein, 2006).
The BCR-ABL gene for CML is a prime example of this type of cancer and perhaps the driving rationale
for targeted therapies. Tumor suppressor genes, on the other hand, are those molecules where their
function, controlling cell proliferation, is disabled. Inactivation of a tumor suppressor leads to an
increased likelihood of cancer development (Weinberg, 2007). Unfortunately, current technology does
not allow the restoration of tumor suppressor function (Flaherty, 2012). When tumor suppressor
function is compromised it is critical to consider the overall signaling pathway in developing therapeutic
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strategies and due to the additional scientific challenges there is the risk of sacrificing the benefits of a
targeted therapy approach.
As sensitivity of testing for mutations improves, distinguishing the key driver mutations from
"bystander" or "passenger" mutations becomes increasingly difficult, as there are a large number of
mutations that occur in any given cancer cell. For example, a study of 33 lung neoplasm samples and
lung cancer cell lines discovered 188 somatic mutations across 141 genes. Most of them were
passenger mutations that were not causal in tumor development (Davies, 2005). Melanoma also
confers a high passenger mutation rate due to carcinogenic UV light exposure (Hodis, 2012). Intense
analysis is required to understand what actually constitutes as a "driver" of tumor growth. The first
TCGA project examined glioblastoma and found eight genes mutated with sufficient frequency to act as
drivers, including alterations in the tumor suppressor NF1, PARK2, and amplifications in AKT3 which
were previously unreported in glioblastoma. (The Cancer Genome Atlas Research Network, 2008). A
recent melanoma study identified six novel genes as potential driver mutations (Hodis, 2012).
Analyses have also shown a high level of interaction amongst potential drivers thereby increasing the
challenge to actually generate a response to an individual targeted agent. Of the glioblastoma samples,
74% of tumor samples contained aberrations in three (Rb, TP53 and RTK) separate pathways (The
Cancer Genome Atlas Research Network, 2008). Within melanoma, almost 44% of those with highly
recurrent mutations in BRAF also harbored a PTEN aberration in addition to several unique
characteristics of p53 mutations (Hodis, 2012). While such observations point toward the rationale for
developing combination regimens of multiple targeted therapies, the success of an individual targeted
therapy is in jeopardy.
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The multiple levels of heterogeneity that exist in each tumor add another later of challenges, making
truly understanding the biology of any given tumor extremely difficult. Genomic profiles differ between
cancer types (or origin of the tumor) but also within the same cancer lineage (within the tumor origin)
and even the cells in the same tumor (Yauch, 2012). A key study, recently published in the New England
Journal, that revealed the extent of intratumor heterogeneity. Of all the somatic mutations found in
four separate tumors, 63% to 69% were not detectable in every sequenced region; therefore a majority
of mutations were not found across all sites of disease within a single patient (Gerlinger, 2012).
Resistance mutations contribute to a tumor's biological complexity, heterogeneity, and possibly limited
impact of a targeted therapy as well. The glioblastoma study found samples of previously treated
tumors were "hypermutated" as compared to those samples that were untreated (The Cancer Genome
Atlas Research Network, 2008). Resistance emerges due to mutations within the same driver present in
a subpopulation of tumor cells, due to acquired mutations or activation of other pathways. Resistance is
perhaps best exemplified by imatinib where soon after its introduction, mutations within the BCR-ABL
gene prevented the drug's inhibition of ABL signaling (Gorre, 2001). Secondary mutations for the EML4-
ALK gene have been reported which contribute to resistance to crizotinib as well (Choi, 2010).
Therefore, any given sample may not inform a tumor's biology and restrict understanding of any given
therapeutics' impact on the tumor and its molecular aberrations.
Scientific Overview for Examples of Complex Biological Targets
Drug targets CDK4/6, MDM2 and P13KP represent examples of emerging biological complexities involved
in regulating known tumor suppressor genes, p16, p53 and PTEN respectively. With deletion of the
entire gene, inactivating mutations in key functional domains, or decreased protein expression, it is the
absence of these molecules that allows others to function in an unopposed fashion. Currently, it is not
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possible to restore the lost function or expression of these molecules and therapeutic approaches are
left to focus on targeting the molecules that are overactive as a consequence of these lost tumor
suppressor genes/protein (Flaherty, 2012). Among other targets, these tumor suppressor genes can act
as biomarkers for inhibition of the protein targets. This class of therapies can be categorized as
"pathway modifying" since the overall pathway is involved in determining sensitivity and a patient's
response to the drug.
CDK4/6 and p16
Activation of specific kinases at various cell cycle states coordinates cell proliferation and halt
progression in response to DNA damage. These cyclin-dependent kinases (CDKs) include CDK4 and
CDK6, which are activated by their regulatory partners, cyclin Ds, and phosphorylate the tumor
suppressor Rb thereby promoting the activation of the E2F genes required for DNA synthesis (Musgrove,
2011).
Figure 4. Cyclin-dependent pathway and function (Musgrove, 2011)
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INK4A, also known as CDKN2A and p16, acts as an inhibitory protein to CDK4/6 as it competes for
binding with cyclin D and prevents the catalytic activity required to drive the cell cycle (Knudsen, 2010).
p16 arrests the cell cycle during senescence when cyclin Ds are released and p16 therefore acts as a
negative regulator of CDK4/6 and overall cell cycle progression (Shapiro, 2006).
The cyclin D-CDK4/6-p16-Rb pathway is disrupted throughout cancer types by differing lesions.
Although Rb loss occurs frequently in some cancer types the majority of tumors increase the activity of
CDKs and retain wild-type Rb. Increased CDK activity can occur through a variety of mechanisms but the
most common is p16 inactivation. Loss of p16 can be achieved through several mechanisms including
mutations, deletion, allelic loss, and epigenetic silencing of the gene, etc (Shapiro, 2006). Since p16
normally inhibits CDK4/6 function and helps to control progression through the Rb pathway, the loss of
p16 expression or function allows CDK4 to signal in an unopposed fashion and drives aberrant cell
proliferation (Witkiewicz, 2011) and is functionally equivalent to inactivating Rb (Knudsen, 2010). Other
disruptions in this pathway leading to tumorigenesis include overexpression of cyclin D1 and CDK4/6.
Cyclin Dl overexpression can occur through a variety of mechanisms such as gene rearrangement,
translocations, amplification, and mutations although none are required (Shapiro, 2006). CDK4, itself,
can have activation mutations and amplifications similar to the HER2 protein (Flaherty, 2012). The
differing lesions complicate the understanding of what aberrations are critical in any given tumor. For
example, a study of 206 glioblastoma samples found that the Rb-pathway was altered in 78%. However,
only 52% and 11% were due to homozygous mutations and deletions in p16 and Rb, respectively while
18% had amplifications of CDK4 (Kundsen, 2010). Further understanding of the driver of any given
tumor will need to specified, not only to the tumor type, but also the specific lesion driving cell
proliferation in the cyclin D-CDK4/6-p16-Rb pathway.
26
A key consideration for targeting this pathway beyond the varying lesions is which one acts as the
biomarker for denoting sensitivity to a targeted therapeutic. Since p16 normally negatively regulates
CDK4/6 it is hypothesized that p16 loss, which is common in many cancers including pancreatic and
melanoma, would denote sensitivity to CDK4 inhibition. However, p16 can also be overexpressed in
several cancers, including breast and small cell lung cancer. The overexpression can be either the cause
or result of Rb loss leading to the need for additional markers (such as Ki67 for proliferation) to
understand the functional state of the pathway. (Witkiewicz, 2011). There have also been conflicting
reports as to the interaction among the aberrations. Earlier studies yielded that p16 loss is mutually
exclusive with Rb loss or cyclin D1 amplification (Aagaard, 1995) while others have found cyclin D1
overexpression commonly occurs with p16 loss (Shapiro, 2006). To understand each lesion and its
associated biomarker will require significant investigation. Several CDK4/6 inhibitor programs are now
in the clinic and evaluating several of the markers within the pathway to better understand the
inhibitors potential as a therapeutic target and what best confers sensitivity (see Results section).
MDM2 and p53
The p53 protein is a key regulator of the cell cycle where if there is too much stress or damage to a cell's
genome or metabolism, it can induce apoptosis, DNA repair and silencing, thereby controlling the
growth of aberrant cells. p53 is affected by upstream signals as a result of stress and is critical in
directing a cell's fate through various downstream molecules (Weinberg, 2007).
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Figure 5. p53 signaling pathway and function (Brown, 2009)
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With this role, the p53 protein acts as a tumor suppressor gene for cancer cells (Weinberg, 2007). In
addition to acting as a tumor suppressor, studies have shown that activation of the p53 response can be
curative in some animal model tumors (Lane, 2010). It is also one of the most mutated proteins in
human cancers with about 50% of tumors having alterations, mostly mutations and deletions, resulting
in inactivation or loss of p53 proteins (Shangary, 2009). With such a potent role and frequency, the
targeting of p53 using many approaches, including small molecules, has emerged as a key potential
therapy in cancer treatment.
MDM2 (also known as HDM2) acts as a negative regulator of p53 by direct protein-protein interaction.
The MDM2 protein binds to p53 and blocks its activity through multiple pathways: including blocking its
transcriptional activity, exporting the protein into the cytoplasm and/or promoting its degradation
(Alarcon-Vargas, 2002). MDM2 is an E3 ubiquitin ligase that binds to p53 and enables ubiquitin-
dependent degradation, which in turn inhibits p53 transcription since the binding domains overlap
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(Tovar, 2006). The direct protein-protein binding interaction acts through an autoregulatory feedback
loop where their cellular levels are mutually controlled (illustrated by Figure 6).
Figure 6. Autoregulatory Feedback Loop of p53 by MDM2 (Shangary, 2009)
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By inhibiting the MDM2 protein it is thought possible to activate the p53 pathway through blocking the
p53-MDM2 binding site, which leads to stabilization of p53 and its activation (Tovar, 2006). Importantly,
p53 must be genetically normal and expressed for MDM2 antagonist to have an impact on p53 function.
One of the more important observations for this target was the development of small molecule
inhibitors (named Nutlins) of the p53-MDM2 protein interaction. The Nutlins were able to show activity
against human xenografts in preclinical models (Vassilev, 2004), and in a preclinical study all 10 cell lines
shown to express wild-type p53 had their cell cycle progression arrested (Tovar, 2006). The activity is
due to the fact that some tumors retain wild type p53 function and when activated can induce tumor
cell death.
Studies using MDM2 inhibitors have shown the potential biomarker utility of p53 and MDM2. Preclinical
studies and findings from the Nutlin series of MDM2 inhibitors indicate that wild-type p53 is required for
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anti-tumor activity, thereby providing convincing evidence for using p53 mutational status as a
biomarker for patient selection (Vassilev, 2004). It is important to note however, that although 50% of
tumors express wild-type p53, there are likely defects in the overall signaling pathway. Of these
additional defects, MDM2 inhibitors can bypass only upstream signaling molecules. The downstream
signaling molecules may impact the overall effectiveness of the p53 pathway and limit re-activation by
MDM2 inhibitors (Vassilev, 2007). Cells may also retain wild-type p53 because they have found another
way to disable the pathway, which includes overproduction of MDM2. In the preclinical study
mentioned above, one cell line had ~25 fold greater MDM2 amplification and the small molecule
inhibitor was able to arrest the cell cycle, signaling reactivation of p53. MDM2 was further investigated
and results suggested that if MDM2 were amplified or overexpressed, it was the only abnormality in the
p53 pathway and that overall signaling was intact (Tovar, 2006) thus conferring sensitivity to an MDM2
inhibitor (Shangary, 2009). These observations illustrate the complicated biology of the p53 pathway, its
regulators and role in cancer, which needs to be better understood to select those patients who would
respond to such a targeted therapy. While one can reasonably conclude that MDM2 antagonist should
only be developed in p53 wildtype cancers, there are likely other, unidentified biomarkers that would
confer resistance to such a therapy and limit therapeutic impact.
Pl3KP and PTEN
The family of lipid kinases known as phosphoinositide 3-kinases (P13Ks) play a key regulatory role in
many cellular processes including cell survival, proliferation, and differentiation. P13K are part of a
complex signaling pathway in which they transmit signals from various growth factors and cytokines into
intracellular messages. PTEN, a tumor suppressor gene, is the key negative regulator that reverses the
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effects of P13K by dephosphorylating the same site that P13K phosphorylates on the membrane (Stemke-
Hale, 2008).
Figure 7. P13K (Class I) signaling pathway (Liu, 2009)
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PI3Ks are divided into classes based on their structural characteristics and their specificity (Fruman,
1998). Pl3KP is an isoform of Class IA which is a heterodimer consisting of a p110 catalytic subunit
(p1103) and a p85 regulatory subunit. Each isoform has a slightly different functional role in tumor
growth (illustrated by Figure 8). P13KP is an effector for both receptor tyrosine kinases (RTKs) and G
protein coupled receptors (the p1lOct isoform is the main effector for RTKs only). Both Class IA isoforms
are expressed in almost all tissue and cell types but P13KP has a role in integrin-mediated platelet
adhesion, arterial thrombosis and certain kinase-independent functions (Liu, 2009).
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Figure 8. Differential function and role in cancer for P13K Class IA p110 isoforms (Liu, 2009)
Several cancer genomic studies indicate that mutations frequently occur within the P13K pathway and
may be involved in a range of tumor types, suggesting they constitute an attractive target for targeted
therapies. Interestingly, while mutations of the p110ac isoform gene, PIK3CA, have been found in many
of the major (27% breast, 15% colon, 3% lung) and other cancer types, only increased activity and
overexpression, not mutations, have not found for P13KP. Loss of PTEN allows unrestricted signaling by
the P13K pathway and contributes to its role in tumnorigenesis in many tumor types. Loss of
heterozygosity of PTEN is detected in greater than 25% of gastric, breast, melanoma, prostate and
glioblastomna cancers and mutated in 38% of endometrial cancer and to a lesser extent in several other
indications (Liu, 2009).
Pan-P13K inhibitors are in development, however, Isoform specific inhibitors are particularly desirable to
avoid the expected toxicity to the immune system, which is driven by p1108 and p1107 (Liu, 2009) and
normal tissues, which predominantly rely on p110at signaling. P13KP inhibition, in particular, has shown
to be promising in PTEN-deficient cancers. Several studies have shown P13K signaling inhibition with
p110P knockdowns and blocked neoplasia formation when p110a was unable to show inhibition of the
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pathway (Engelman, 2009). These results suggest a strong relationship amongst the pathways and are
important to understand further for therapy development.
Initially PTEN mutations were thought to be the primary driver of deregulation in the P13K pathway but
the varying impact across tumor types leads to some questions of PTEN's utility as a biomarker (Cully,
2006). Complicating its use as a biomarker, PTEN loss can occur not only through mutations and
deletions but also truncated proteins, epigenetic silencing of the gene, complete genetic loss when
starting with one allele, etc. similar to p16 (Flaherty, 2012). Unfortunately although positive results
have been seen with P13K@ inhibitors within PTEN deficient tumors, the mechanism is not known,
thereby limiting the ability to understand how the response will translate into the clinic. The effect may
be only for a portion of PTEN deficient tumors since it is only one member of the pathway. Some PTEN
deficient tumors may be less reliant on p110p through a p1l0a gain of function mutation, for example,
or mutations in downstream signaling molecules (Ni, 2012). These complex interactions still require
extensive investigations to understand each player's role in any one tumor type.
Key Factors for Biomarker Clinical Trial Decisions
The challenges associated with developing a biomarker directed anticancer therapy can limit the clinical
and commercial success of a drug program to the point where a more traditional all-comers approach
for early-stage clinical trials is more appropriate. Among the multitude of factors influencing
commercial success, three are especially important: therapeutic effect within the selected population,
prevalence of the predictive biomarker and performance of the companion diagnostic. These factors
can be used to help guide the clinical trial strategy decisions since other analyses suspect alternative
clinical trial strategies may be more appropriate for targeted therapies.
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Simulation studies have revealed quantitatively that targeted therapies have a significant benefit in
situations where there is a clear risk/benefit profile. For example, if there is a clear scientific rationale
with a true predictive biomarker and the cutoff point for determining marker status is well established,
significant toxicities would be experienced by the biomarker-negative patients (even if modest drug
benefit) or when it would be ethically irresponsible to use an all-comers approach based on prior
studies. Several cases have been documented, however, in which an all-comers approach followed by
additional testing to understand subgroup treatment effect is more appropriate, particularly in those
situations where there is increased uncertainty due to biological complexity, where the cutoff point for
marker status is not well-established, and the treatment has the potential to benefit both biomarker
(positive and negative) populations (Mandrekar, 2009).
Dr. Keith Flaherty of Massachusetts General Hospital has noted that targeted drug developers need to
consider the sliding scales of biomarker prevalence, assay validity/confidence and therapeutic efficacy
when determining their biomarker strategy (Flaherty, 2012). These three key factors were also
confirmed through a modeling study performed through the Massachusetts Institute of Technology
(MIT) Center for Biomedical Innovation. The team, which included participants from MIT, FDA,
pharmaceutical industry, diagnostics industry, and international academicians, performed modeling
simulations and analyses on over 90 factors across two case studies to understand the factors
influencing the success of stratified medicine therapies. A key element of the study was to evaluate and
compare the expected net present value of each drug depending on the clinical trial design. Four
different pivotal (late-stage) clinical trial design strategies were used: all comers, all comers followed by
retrospective biomarker analysis and a confirmatory biomarker-positive trial, biomarker-positive only
enrollment, and a dual strategy incorporating biomarker arms in an all-comers context (Trusheim, 2011).
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The case studies of trastuzumab and panitumumab are especially relevant from this study where the
modeling documents the benefit of prospectively using a biomarker-positive only enrollment strategy.
While panitumumab would have added only 9.8% to the economic value with a biomarker-positive only
strategy, trastuzumab would have had only 29% of the eNPV with a traditional all-comers trial. This
difference in value illuminates how critical biomarker validation can be as trastuzumab had a clear
biomarker hypothesis before phase i development began and panitumumab began with EGFR
overexpression only to realize that KRAS status was the key determinant of response. While all four
scenarios found a biomarker-positive only enrollment approach superior, the authors stated that if there
were weaker predictive biomarkers or a lower therapeutic efficacy the clinical trials would have required
more patients and impact on the overall benefit of a stratified approach. The need to screen patients
with a companion diagnostic also increases the complexity and duration of the clinical trials, again
affecting the overall eNPV value. Additionally, the authors specifically noted that those projects where
there is limited prior knowledge for the clinical performance of the predictive biomarker or complexity
of a novel companion diagnostic may actually prefer an all-comers clinical trial design strategy due to
the lower probability of clinical and technical success of a stratified approach (Trusheim, 2011).
Sensitivity analyses revealed the same three factors mentioned by Dr. Flaherty interacted "particularly
closely to affect economic value". Therapeutic efficacy within the selected population, prevalence of
the predictive biomarker and the performance of the companion diagnostic were further interrogated
to understand the tradeoffs involved. The retrospective modeling analysis found that in determining
commercial success there was no specific threshold required for either prevalence of the biomarker or
performance of the companion diagnostic but shortcomings in either area needed to be compensated
by the other along with and an improved therapeutic effect (Trusheim, 2011). A key question still
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remains however, as to how and on what basis to make these critical decisions early in the drug
development process with the scientific knowledge gap that exists.
3. Study Purpose and Methodology
Study Purpose
Despite and perhaps even because of the multitude of challenges and tradeoffs associated with
developing targeted therapeutics as discussed above, drug developers must still use the information at
hand to guide clinical trial stratification decisions. Three key factors have been shown to be especially
significant in this decision process: therapeutic efficacy, biomarker prevalence and companion
diagnostic performance as discussed above. Unfortunately, at the time these decisions are typically
made, true clinical therapeutic efficacy is not known, given how complex and heterogeneous tumor
biology can be. The two factors drug developers can consider are the biomarker prevalence and the
sensitivity and specificity of a planned companion diagnostic, however, these can be widely variable and
thresholds could be used for each factor to support the rationale for early stage clinical trial strategy
decisions.
Using a sample of drug targets that represent the increasing tumor biological complexity (CDK4/6,
MDM2 and Pl3KP), in this thesis I hypothesize that early stage oncology drug developers do, in fact,
establish minimal thresholds for both biomarker prevalence and companion diagnostic
sensitivity/specificity when determining strategies of all-comers versus biomarker stratified clinical trials
for targeted therapies. To evaluate this hypothesis, I examine several programs that are in the
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preclinical stages or have clinical trials in progress, which provides me with empirical data on how these
key factors are being incorporated into the implementation of the strategic clinical trial design decisions.
Literature Review and Information Interviews
An extensive literature review was carried out to understand the key business and scientific drivers and
challenges for targeted oncology therapeutics. This review was conducted across scientific, clinical,
regulatory, statistical, economic, and mass media sources. Additionally, several interviews were
conducted to understand challenges for both the drug and diagnostic industries. Key insights acquired
during these conversations are incorporated into the Background and Discussion sections. Finally,
discussions held at conferences on personalized medicine and clinical oncology I attended helped to
understand the key challenges clinicians and drug developers are grappling with and their perspectives
on resolutions to move forward. The findings informed what types of inquiries would be needed to
answer the questions posed and placed the responses in the context of the overall development of
targeted therapies. This enables me to gain insights on key implications for future decisions on guiding
clinical trial decisions for targeted oncology therapies.
Target Selection
The selection of targets used as the focus of this thesis was chosen after speaking with Dr. Keith
Flaherty, both an advisor to this thesis and a well-known principal investigator in oncology studies. He
has a unique perspective for targeted oncology therapeutics, since he is involved with a multitude of
selective compounds and has had success with the BRAF inhibitors, specifically serving as principal
investigator for several vemurafenib clinical trials.
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Selective inhibitors that have negative regulators are a relatively new area of drug development and
there are several programs that allow for a focused study. Several sources were used to identify the key
programs from which to draw interview participants, including expert investigators and drug
development databases/data aggregators. Dr. Flaherty knew of several key programs and this
information was verified and augmented through searching Thomson Reuters Pharma. Thomson
Reuters Pharma lists programs based on a target and extensive information on a compound's
development. Additionally, this information was cross-checked with Adis, a R&D pipeline database.
This approach yielded ten programs across the three targets as the example dataset. A summary of
these targets, programs and associated progress is provided below. The programs exist across nine
different large pharmaceutical companies with only one company having more than one program. The
programs were initiated both internally and in-licensed from smaller firms.
Table 3: Summary of Relevant Programs
Inhibitor Target Development Company Originator Company Development Phase
CDK4 Eli Lilly and Company Eli Lilly and Company Phase 11
CDK4 Novartis AG Astex Therapeutics Ltd Phase I
CDK4 Pfizer Inc Onyx Pharmaceuticals Phase 11
MDM2 Amgen Amgen Preclinical
MDM2 Boehringer Ingelheim Nexus Pharma/Priaxon Preclinical
MDM2 Roche Holding AG Roh oligA Phase I
MDM2 Sanofi Sanofi Preclinical
PIK3-beta Bayer Bayer Preclinical
PIK3-beta GlaxoSmithKline GlaxoSmithKline Phase 1/11
PIK3-beta Sanofi Sanofi Preclinical
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Interview Guides
An interview guide was created to evaluate the hypothesis that drug developers have established
thresholds for biomarker prevalence and companion diagnostic performance for their "pathway
modifying" programs. Additionally, several questions were aimed at gaining insight into the larger drug
development strategy for such programs. Initially, there was some concern as to whether interview
participants would be willing to provide quantitative information on very early stage programs. In order
to mitigate this challenge, additional follow up questions were used to ascertain an operating range for
a given threshold.
Each interview was formulated as a discussion around drug biomarkers and companion diagnostic drug
development that addressed each of the following questions:
1. What biomarkers are you currently using to direct development and/or select patients for your
program?
a. Would the biomarkers be considered dichotomous or continuous?
i.e. would the "operating characteristics" of the assay require cutoff points established
between positive and negative results?
2. Are you currently planning to pursue a companion diagnostic for your program?
a. What types of platforms are you evaluating for a companion diagnostic?
i.e. genotypes, proteins, IHC, immunoassays, next generation sequencing
b. If yes, what is the expected sensitivity and specificity of your planned assay? Is there a specific
range in which you expect the companion diagnostic to perform?
i. If the sensitivity/specificity was found to be lower would you still pursue a companion
diagnostic approach?
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1. At what degree of performance would you no longer consider using the
companion diagnostic or abandon the biomarker?
2. In the absence of a companion diagnostic, would you still pursue the program?
c. If no, why and is there any situation in which you would reconsider the approach?
i. What level of confidence would you need to see in an assay to move forward with a
companion diagnostic strategy?
i.e. what efficacy in biomarker positive population versus lack of efficacy in biomarker
negative population?
3. What is the prevalence of the biomarker within the targeted population or indication?
a. If the prevalence were higher or lower would that change your development approach?
4. Would you expect to include all methods of negative regulator loss in one assay?
i.e. would you expect to capture all populations of potential patients or only the group that can be
identified through a single assay?
a. Which would you expect to use: multi-marker assays using one method (such as sequencing
all exons of PTEN/p53/cyclin D/p16) versus a multi-modality assay that incorporates genetic
and protein-based information? Why?
Interview Participants
In order to capture the development strategy from several perspectives for each identified program, the
preclinical, clinical and translational leaders were targeted for interviews. Each role has its own
rationale including them in the dataset. Insight from the Clinical Lead is critical as they are the
individuals ultimately responsible for the strategy and decisions required for clinical testing.
Understanding the impact of companion diagnostics and patient selection is absolutely critical to moving
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a program through the development path and will ultimately impact the drug's approval decision. Since
these programs are in the early stages of development the Preclinical Lead provides valuable
information regarding biomarker use and assay development/validation, which is a key analysis point for
this thesis. A Translational Lead is responsible for understanding how the assay performance impacts
compound development and therefore provides insight surrounding challenges in developing a reliable
companion diagnostic and its impact on therapeutic development. While not all three roles may be able
to completely answer all questions discussed above, this collection of perspectives provides both
verification for an individual compound strategy and a view of the challenges for biomarker based drug
development.
Points of contact for each program were identified through personal professional network contacts and
thesis advisors. Additional interviewees were identified through preceding interviews. A total of 17
interviews were conducted across the different programs and roles. Interviews were conducted across
nine of the ten programs. There was equal representation across the different programs with six, five
and six interviews conducted for the CDK4, MDM2 and P13KP programs respectively. A total of six
clinical leads were interviewed while five interviewees were preclinical leads and five were translational
leads (one interviewee was both the clinical and translational lead).
To maintain confidentiality, the responses collected from the interviews will be reported in aggregate.
Clinical development strategies and the information used to support that process are proprietary and
therefore both the identify of the interviewee and the associated company will not be disclosed.
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Clinical Trial Designs
The published clinical trial protocols can provide insight on the strategies and decisions for those
programs that have already entered the clinic. These protocols were found through searching the public
database clinicaltrials.gov on the particular target (CDK4/6, MDM2, P13K@) or the compound name if
previously identified. While the extensiveness of the protocol details vary depending on the sponsor,
any molecular stratification would be included in the description or inclusion/exclusion criteria and
therefore can provide valuable insight on actual strategy decisions.
4. Results
Biomarker Descriptions
The biomarkers being investigated by the drug programs and their characteristics were similar to what
was expected and detailed in the background section of this thesis. However, one of the key differences
from expectations involved the fact that several of the programs were using the most conservative or
simplistic definition of the biomarker.
CDK4/6 Inhibitors
CDK4/6 inhibtor programs are investigating the use of several biomarkers including p16 loss but also
(and in some cases more importantly) Rb status, cyclin D amplification and CDK4/6 amplification. While
p16 loss is one way the tumors proliferate, there is essentially a parallel process where cyclin D levels
rise and activate which then activates CDK4/6 and that complex inhibits Rb and allows cell cycle
progression when it should not, as is the case in tumorigenesis.
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Rb status was considered the most important biomarker by the interviewees since preclinical data
indicates that a CDK4/6 inhibitor would not work within a tumor where Rb was non-functional (or had a
negative status). Therefore, Rb was considered a dichotomous biomarker; it was either positive or not.
Rb was considered by one interviewee to be the direct target while the other biomarkers were more of
a mechanistic question where they were only a part of the pathway, not the desired measurement of
response. The other biomarkers were considered continuous but interestingly there was less clarity
about testing methodologies and all were being considered in different contexts as compared to
biomarkers for the MDM2 and P13K@ programs.
The interviewees expressed concerns that since there were multiple modalities for achieving p16 loss
and overexpression of cyclin D and CDK4/6 they were unsure as to what method would be most
appropriate. Loss of p16 would include protein expression assays (IHC) where a level of expression
would need to be defined as sufficient "loss". One interviewee, however, indicated that comparative
genomics would be useful for p16 (as well as Rb) that would make the categorization more
dichotomous. Expression levels of cyclin D and CDK4/6 would need to be defined as low or high and
characterized by the level at which it contributed to tumor growth and patient response with a similar
protein expression assay. Adding to the confusion, the interviewees raised the possibility that
overexpression was not necessarily the same as gene amplification, with this still needing further
investigation. Similar to p16, methods of loss exist that would make cyclin D and CDK4/6 more
dichotomous. Cyclin D can have translocations, which simplifies the categorization, and CDK4/6 can
have mutations, again classifying it as a dichotomous biomarker.
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Additionally, the biomarkers could be indication-specific as an interviewee illustrated substantial
evidence exists suspecting that p16 loss in melanoma is a driving event, while in liposarcoma almost all
patients have CDK4 amplification.
MDM2 Inhibitors
For MDM2 inhibitor programs the identified biomarkers were p53 mutation status and MDM2
amplification. p53 mutation status was considered dichotomous by all interviewees but several nuances
were raised. For example, while having a p53 mutation may be a yes/no categorization, once you know
the gene is wild-type there could be a more continuous response to consider. For example, there may
be downstream mutations or signaling issues that would impact the level of response to an MDM2
inhibitor. This is where the retrospective studies may help indentify and describe sub-stratifications that
could become useful in understanding a patient's response. Additionally, one interviewee raised a
larger issue that while mutation status may be dichotomous now, it will be important to consider the
sensitivity of the detection test in making patient treatment decisions. His/her concern was that the
sequencing was now so sensitive that it could pick up p53 mutations that did not have an impact on
function and therefore would exclude a segment of patients that may benefit from an MDM2 inhibitor.
It was stressed that much still needs to be learned on the impact of specific mutations on functional
status. Despite these concerns, however, the interviewees envisioned p53 status as the first line of
patient stratification.
MDM2 amplification was less defined and although interviewees felt that it was characteristically more
like a continuous curve, there was the possibility to fit it into a dichotomous decision. It comes down to
whether or not there is amplification. The fact that there is already a defined algorithm for what is
amplification helps make the decision more clear in one interviewee's opinion. Several added layers of
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considerations include how much amplification is needed for patient response and the issue of
overexpression vs. amplification. It is possible for a patient to have overexpression of MDM2 without
amplification and whether or not the drug would benefit those patients is an unresolved issue.
Pl3KO Inhibitors
PTEN loss was the primary stratification measure and was considered to be a continuous biomarker by
the interviewees, since it is most frequently determined by protein expression assays (IHC). It is
necessary however to create a cutoff to move forward with clinical development. One interviewee
stated that his/her program was using the most stringent cutoff in the literature and putting it where
they expected to start seeing noise in the assay. In this case, it was 10% staining or less as a defined
cutoff. The program considered putting it at 100% absence of staining but they were afraid that they
would be unable to find patients. Without knowing the distribution of IHC results in the population it
was difficult to know at what point was it the most appropriate and feasible to conduct a clinical trial.
Another interviewee stated that there is no hard number as to what is PTEN loss but he/she hoped that
a binary curve would appear in the clinical data. Another interviewee stated, however, it is too early to
tell. The confusion stems from the fact that although there may be staining it is important to know at
what point does the protein become non-functional. This determination will require further
investigation and may allow the patient population to expand as more is known about the biomarker.
Companion Diagnostic Performance
Not surprisingly given the recent successes and regulatory environment for targeted oncology
therapeutics mentioned in earlier sections, all programs interviewed are at least planning to use a
companion diagnostic as part of their strategy. When asked about the targeted companion diagnostic
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performance (sensitivity and specificity), however, only a few interviewees responded with a desired
range. One interviewee referenced that past IHC performance characteristics included about 20% of a
"gray zone" and therefore a companion diagnostic would need to perform at least at an 80% level.
Another interviewee stated that the FDA requires 90% concordance but a level of around 85% could
possibly be acceptable. Two other interviewees stated that the diagnostic would need to be at least
90% sensitivity and specificity. Finally, another interviewee referenced the current performance of
sequencing companies, such as Foundation Medicine who presented at the American Society of Clinical
Oncology (ASCO) meeting this year, where they could detect approximately 5% mutants 100% of the
time and less reliably for mutants at lower frequencies.
Several of the interviewees stated that it was too early to understand the performance they could
achieve and as one stated, they would need the expertise of a diagnostic company and regulatory
authorities to better understand the requirements. It is known that a certain level of rigor is required
but the program leads did not state the desired level.
The technical performance levels were also considered to some extent variable depending on the type
of activity or response in patients. One interviewee was more concerned with at what level would you
see a difference in activity as opposed to a certain specificity. Another mentioned that it was more of a
consideration between efficacy and safety. For example, if there were some response in the biomarker
negative population then the companion diagnostic technical specifications would be more focused on
the safety of those patients being exposed to toxicities. Two interviewees considered a threshold of
companion diagnostic performance to be too simplistic to grapple with the tradeoffs of sensitivity and
the number of factors that would need to be considered.
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The interview participants were asked whether the drug program would continue if it were unable to
validate an assay and reliably identify the appropriate patients in a clinical setting. Stated another way,
they were asked whether the program would continue if the companion diagnostic could not achieve a
technical performance level to be defined at a later date. The interview participants responses ranged
in confidence but almost 60% (n=9 of 17) said that they did not expect the program to continue without
a companion diagnostic. The 40% that felt the program could continue in some way varied in their
reasoning. Several interviewees were unable to say that the program would be discontinued but did
mention it would be difficult for it to continue but might be deprioritized. An example would be the
program could continue in an indication where the biomarker prevalence was extremely high but most
likely it would be an ultra-small indication (less than 3,000 patients). This market size would be difficult
to support a business case. One of the interviewees who stated the program would not continue
specifically mentioned that if the market were large enough for a business case then it would need a
companion diagnostic. Interestingly, a few interviewees discussed the possibility of the program
continuing as long as there is drug activity (patient response), perhaps being used in a combination
setting or as an immunoadjuvant.
Biomarker Prevalence
Thresholds for biomarker prevalence in guiding clinical trial stratification decisions were also highly
variable. Responses for at what level of biomarker prevalence would allow an all comers trial to be
appropriate ranged from 50% to examples as high as 99%. One interviewee stated that thresholds were
being used but the levels that were considered proprietary. The remaining interviewees expressed
concerns that an all-comers trial would never be appropriate.
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On the lower end of thresholds, three interviewees established 50% as a possible threshold for an all-
comers strategy if the drug activity were significant enough. As one of the interviewees stated, you
could take all patients, but you would not expect full activity. That same interviewee cautioned
however, that even if the biomarker prevalence were at 80% it would be important to consider the
biological complexity. If there is known interaction between targets it may not be possible to trust
patient responses will behave in a similar manner. On the high end of the thresholds, two interviewees
used the example that if only 1% of any given patient population were excluded (i.e. a biomarker
prevalence of 99%) that a companion diagnostic would not likely be developed. It was important to
note however, that if the drug was applicable across multiple cancer types that the companion
diagnostic would again need to be considered. Two interviewees fell into a more intermediate range.
One interviewee stated that if the biomarker prevalence was above 70-80% then he/she would consider
not developing a companion diagnostic. The other interviewee was a bit more conservative, stating that
if the prevalence were greater than 80-90% they would feel comfortable without patient selection. The
final interviewee stated that thresholds were being used for selecting patients onto a trial, but the
actual range was considered proprietary.
A few interviewees were unable to provide a range in which they thought an all comers trial would
become appropriate due to ethical considerations. One interviewee thought that a companion
diagnostic was critical regardless of the biomarker prevalence but conceded that it depended on how
clear the stratification was. For example, if some biomarker negative patients received a benefit, it
would be more difficult to require only biomarker positive patients. With a high prevalence of 50-60% it
could be possible to use an all comers strategy, stated one interviewee, but the ethics of harming
patients that may not receive a benefit "trumped" including them in the trial.
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Most of the interviewees used this question as a springboard to also discuss whether there was a
minimum biomarker prevalence to encourage program development. The responses ranged from no
required minimum to indications being prioritized above 20% biomarker prevalence. A few interviewees
mentioned that there was not a minimum requirement for prevalence or incidence; if there were an
unmet need and the company had a potential drug then it would be pursued. One interviewee
mentioned that a minimum threshold depended on the attitude of the company. Past successes and
failures can impact the minimum requirement in either direction. For example, one company had a
prior failure with a less selective molecule and therefore would most likely not move a more selective
one forward if it were only a small applicable patient population (the previous failure "poisoned the
probability of success"). However, another company's success with a small indication could allow it to
consider other small indications with high biomarker frequencies. This interviewee mentioned however,
that an indication with a small patient population and only moderate biomarker frequency would most
likely not go far in development. Four interviewees provided a threshold of biomarker frequencies
below 5% would most likely not be investigated within their organizations. The highest minimum
prevalence given by one interviewee was that the company wanted prevalence of at least 20%.
Indication decisions for one company (per an interviewee) involved stack ranking the indications by
biomarker frequency and choosing to keep the top ten as indication options. The size of the indication
mattered however. An indication that would have been discarded due to the frequency was included in
the final list due to the indication size being very large ("big 4" cancer types). Interestingly, another
interviewee used the example of the "big 4" where the company would tolerate lower frequencies of
biomarker prevalence at 10-15% while for ultra-small indications (<3,000 patients) then a prevalence of
at least 75% would be desired. One of the key considerations for one interviewee was whether it would
be possible to accrue a clinical trial both from overall patient numbers but also what potentially would
still be available after taking into account competitor compounds.
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Clinical Trial Designs
A total of thirteen clinical trials were in progress or completed across the ten programs
(clinicaltrials.gov). Twelve were company sponsored while only one was investigator sponsored. Of
those thirteen trials, 54% (n=7) had a molecular biomarker inclusion or exclusion criteria included in the
protocol that signaled biomarker stratification while 46% (n=6) were enrolling on an all-comers basis.
The lone investigator sponsored trial was a phase || trial that included biomarker-based enrollment.
Figure 9. Published clinical trial strategy decisions
Biomarker based enrollment increased as the development phase advanced, however, there were still
almost as many biomarker based enrollment strategies in the phase I trials. For those trials in phase I
all were using a biomarker restricted enrollment strategy.
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Figure 10. Published clinical trial strategy decisions by phase
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Interestingly of those six trials enrolling first as all-comers, three included biomarker enrichment or
correlation as part of expansion plans (one in phase I and two in phase 1/11). An additional trial was also
being planned to require a mutation in the pathway as part of expansion per an interviewee (although
not detailed in the published protocol).
Despite interviewee responses regarding using the drug in combination therapy without a biomarker,
the therapy type did not appear to affect the stratification decision. Each strategy had around 50% of
their trials as each therapy type - combination or mono therapy.
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Figure 11. Published clinical trial strategy decisions by therapy type
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Interviewees also provided information on the plans for programs still in the preclinical stage. Two
programs planned to start enrolling as all comers in phase I. However, expansion plans would include
enrolling a specific proportion of indentified biomarker patients in those indications with high
prevalence of the desired biomarker.
5. Discussion
In this pilot study I have examined the factors of prevalence and companion diagnostic performance and
their impact on biomarker-guided clinical trial strategy decisions. In addition, I have evaluated the key
challenges facing drug developers of complex biological targets using the representative "pathway-
modifying" drug programs. Interviews with leads of drug programs for CDK4/6, MDM2, and Pl3KP
inhibitors were conducted to understand these factors and.their implications for overall development
for targeted oncology therapies. The thresholds of prevalence that would lead to using an all-comers
clinical trial strategy as opposed to a biomarker-guided strategy varied widely from approaching 100%
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down to 50% depending on several factors including drug activity, toxicities, biomarker separation and
ethical concerns. Companion diagnostic thresholds were even less common where the majority of
responses implied that additional expertise and investigation was needed to guide those decisions.
While the hypothesis that common prevalence and companion diagnostic thresholds were being used to
guide these clinical trial decisions was not supported, several valuable insights were gathered from
interviews with drug development experts.
Limitations
This study was meant to act as a pilot and therefore is informative of trends and considerations in
developing stratified therapies but small sample size prohibited my examining any possible statistically
significance. The molecular targets and drug programs were chosen to represent the expected
biological complexity of targeted therapies, and therefore are certainly not representative of all targeted
agents in development. Although the drug program dataset was not meant to be this, all ten programs
were limited to large pharmaceutical companies. Different considerations and factors may be
considered by smaller or biotechnology companies.
Additionally, while three interviewees (Preclinical lead, Clinical lead, and Translational lead) were
targeted from each program, the response rate overall was 58.6% (n=17/29) due to time constraints and
challenges in identifying the appropriate individuals and scheduling time for an interview. Therefore,
conclusions are limited by potential biases that exist in the respondents despite having an almost equal
number of responses across the roles. Another limitation is that some responses were incomplete due
to the interviewee's desire to keep proprietary information confidential. The level of knowledge of each
discussion item (prevalence, companion diagnostics, diagnostic methodologies, etc.) also varied across
53
the different respondents. Some interviewees were hesitant to answer questions outside of their
knowledge base or responsibilities, and in some cases stated that they were speaking speculatively or
hypothetically. Importantly, each of these responses in the interviewee's opinion or perspective is not a
quantitative datapoint and can therefore limit hard conclusions. However, these perspectives do
provide valuable information on the factors considered and the direction of activities as stratified
medicines face considerable challenges ahead.
Extent of Uncertainty for Companion Diagnostics
A key unexpected theme of the interview discussions was the extent of uncertainty surrounding
companion diagnostic utility and performance. Only a few interviewees were willing to suggest a range
in which a companion diagnostic should perform and even one of those used past diagnostic approval
examples (HER2 testing) as a reference. No interviewee responded with regulatory requirements, which
is not unexpected since there is still a great deal of ambiguity for companion diagnostics development
and biomarker validation. The response is somewhat surprising, however, since in order to support
approval, the company will need to show the regulatory authorities, including the FDA, that it can
reliably identify those patients who are expected to respond to the targeted therapy. Without
understanding the ability of what is needed to detect those patients, late-stage clinical trials could be
more technically challenging and more costly. Omacetaxine (Omapro, ChemGenex) is a recent example
of the risks associated with not achieving strong enough analytical performance. The drug, for CML, was
tested with different biomarker diagnostic testing protocols at different sites but they could not reliably
demonstrate what population was actually enrolled in their trial. The drug was submitted in Sept 2009
and is still not approved since they have not presented a test that selects the same population they did
in their trials (Mansfield, 2012). The respondents did seem to recognize this type of risk since the
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majority of them (almost 75%) stated that they thought their drug program would either not move
forward or be deprioritized if the companion diagnostic could not be developed.
Companion diagnostics technology is also continually evolving, which can limit the establishment of a
standard. Despite its being approved over a decade ago, there is still no gold standard for HER2 testing
and quality of the assay performance was considered a major issue in the later stage randomized clinical
trials (Carden, 2010). Both IHC and FISH methodologies are used and while several test kits are FDA
approved, a CLIA laboratory can also perform testing with various reagents and protocols. Surprisingly,
the concordance between the two tests can be as low as 25% as a result of the various inconsistencies
(Bilous, 2003). Additionally, Dr. Stephen Spielberg of the FDA at the 2011 Personalized Medicine
Conference said that the technology for companion diagnostic is changing faster than that for
therapeutics (Spielberg, 2011). A key example is how whole genome or next generation sequencing will
impact IVD testing. It was clear from the interviews that these drug developers were grappling with
these same issues. Several respondents noted that the role of sequencing was still to be determined but
there were concerns that it is not the "be all end all" for companion diagnostics. Not only are some
aberrations (such as epigenetic silencing) not detected through sequencing, but the function of each
mutation still needed to be determined. As previously mentioned, one interviewee stated that the
sequencing was becoming so sensitive that it was becoming difficult to understand which mutations
were important for function and therefore relevant for targeted therapies. When asked about the
assays being used in developing a companion diagnostic, interviewees stated that several
methodologies were still being considered, even in those compounds already in clinical trials. IHC versus
FISH was a common consideration but new methodologies such as chromogenic in-situ hybridization
(CISH) and sequencing were also options for companion diagnostic assays. Only one program was using
a validated assay but it was still unclear whether it would serve as the companion diagnostic to support
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pivotal trials. Therefore, while companion diagnostic technology may be changing more rapidly than
therapeutics, the process of assay and biomarker validation is actually lagging behind the drug
development process (Carden, 2009).
Conservative Biomarker Cutoffs
Another key topic emerging from the study was the fact that while interviewees recognized biomarkers
could be continuous, in almost all instances the drug programs would move forward using conservative
biomarker cutoffs. This could be in fact a way of drug developers compensating for the biomarker
validation uncertainty. For example, in those programs where tumor suppression loss could occur
through multiple mechanisms (p16 and PTEN), respondents asserted that the cutoff for selecting
patients would be complete loss, as opposed to varying levels of expression. Dr. Elizabeth Mansfield,
Director of Personalized Medicine staff of the FDA's Office of IVD/CDRH suggested that the FDA would
like to gather information the extent various populations benefit from a therapy whether it be lower
protein expression levels or rare genetic mutations (for example a BRAF mutation that was not V600E)
and in order to gain approval for these "other" subpopulations, some data would have to be seen on
them. However, she conceded that the companies did not know how to anticipate what the FDA would
do if their data comes back lower than with a more conservative cutoff. These companies are therefore
reducing the risk on a regulatory level as well. There are several examples of companies using a more
conservative cutoff and then using anecdotal evidence from physicians on a treatment effect to drive
further trials to expand the overall market to new subpopulations or indications (Mansfield, 2012).
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Variation in Prevalence Thresholds
The level of variation in the suggested biomarker prevalence thresholds, from 50% to 100% required for
an all-comers trial may illustrate the effects of complex biological targets and the impact of not being
able to estimate potential therapeutic efficacy. If strong drug activity and responses are seen, lower
levels of biomarker prevalence would be needed in order to demonstrate clinical benefit. The levels of
uncertainty are so great that the early-stage trials are merely providing information rather than
validation of a biomarker. Several interviewees also suggested this when they considered drug activity
the primary objective and biomarker correlation only secondary. In a discussion of using biomarker-
based patient selection in phase I trials, a group of authors state that "to date, many of the biomarkers
used in clinical trials of novel agents have been exploratory and not well validated, leading to inefficient
or unsuccessful deployment" and often introduced too late to have an impact on early clinical trials
(Carden, 2010). This particular sentiment seems also true for the programs that represent complex
biological targets and served as this study dataset. It is also possible that for such targets where it is not
possible to understand potential therapeutic efficacy that prevalence of the biomarker should not
impact clinical trial decisions; a phase I all-comers trial may be more appropriate. Further evaluation
and modeling will be required in order to understand what prevalence levels are appropriate for varying
clinical design strategies and importantly, at what levels will drug developers undertake the challenge.
Dr. Mansfield stated that the FDA had addressed prevalence a couple times where the biomarker is a
diagnostic determinant of disease (similar to BCR-ABL CML, Philadelphia-positive acute leukemias). In
these cases, the diagnostic is not considered a companion and would not affect approval. In her
opinion, there was not a particular number at which using an all-comers trial throughout clinical trials
was appropriate but if the biomarker prevalence was 90-95% then in many cases a companion
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diagnostic would not be needed. It would depend on how much harm comes to the other
subpopulation, however (Mansfield, 2012).
An unexpected yet fascinating finding of this study was the levels of prevalence drug developers thought
would continue through the drug development process. Although some interviewees stated that as long
as there was an unmet need they would pursue the target, several used the example of crizotinib and
ALK as a threshold where the biomarker prevalence was only around 5% of non-small cell lung cancer.
Although no longer possible, it would have been interesting to understand what perspectives would
have been without such a visible example of success. As a contrasting example, while CML was a small
indication, the biomarker effectively defines the disease and therefore approaches 100% prevalence.
Interviewees stated that it was not just the prevalence of the biomarker but also the size of the overall
indication in which the subpopulation would reside that would influence their decision to pursue that
target. The opposite was also true where although a given ultra-small indication (<3,000 patients) was
close to 100% biomarker prevalence, several interviewees felt that the target would not be pursued
unless it was applicable in a wider range of cancer types. Further clinical studies and which indications
are included would shed light on what levels of prevalence and indication size are needed to justify
targeted drug development.
Emerging Alternative Clinical Trial Strategies
Several alternative clinical trial designs and recommendations are now being considered to potentially
deal with the high levels of ambiguity. The use of expansion trials was a key finding through the study
interviews that echoes recommendations put forth in the literature and elsewhere. Four of the six
clinical trials using an all-comers strategy to start phase I or phase I/Il studies were planning to enrich an
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expansion cohort. This was also a strategy undertaken by several of the successful targeted therapies,
including vemurafenib and crizotinib. It is important to ensure safety and gather appropriate PK/PD
data in a large enough patient cohort during a dose-escalation phase. Donna Neuberg, a biostatistician
at the Dana Farber Cancer Institute mentioned it will be difficult to understand any off target effects in
only single arm trials. She recommended starting with all-comers and then differentiating prognostic
factors in subpopulations (Neuberg, 2012). Several sources suggested that casting wide nets in early-
stage clinical trials allowed for identifying possible predictive biomarkers, which can then be followed by
integration of the biomarker into further trials to correlate the clinical benefit. Testing many hypotheses
could be accomplished by using smaller and more seamless, adaptive designs in phase 1/11 (Bradley,
2012). Dr. Anthony Tolcher during a presentation at the American Society for Clinical Oncology (ASCO)
2012 meeting recommended a unselected phase 1, then expansion cohorts and phase 11 should include
cohorts of molecular "hot sites" to deal with the disadvantages of pre-selecting early stage trials,
including the level of molecular complexity (Tolcher, 2012). Through using an adaptive approach and
allowing cohort enrichment it is possible to accelerate development by performing hypothesis testing
studies in phase I expansion cohorts (Yap, 2010).
It is interesting to note however, that 40% of the clinical trials already in progress for the study drug
programs were using a biomarker-selected only population in phase I and 1/11. These trials are forgoing
the benefits of wider PK/PD data due to what they believe is a strong scientific hypothesis despite the
challenges in identifying the targeted patients. A common statement in the literature is that for those
compounds with unknown mechanisms of action, multiple potential targets or broad-spectrum
inhibitors, biomarker-based evaluation may not be appropriate (Carden, 2010, Yap, 2010). A critical risk
of using biomarker-selected only populations is that data is not collected on the responses of the
biomarker-negative population in early-stage clinical trials. Dr. Robert Temple of the FDA's CDER
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department stated that the FDA believes you have to "know something" about the "other group" but
there is uncertainty as to what extent is necessary (Temple, 2008), which could threaten the approval of
the agent. Dr. Mansfield mentioned that initially the FDA thought drug/diagnostic developers would
pursue a predictive claim and use biomarker positive and negative populations in trials. However, Drug
developers have moved to only needed to be able to select the same patients reliably and therefore the
analytical rigor and performance in a single arm is enough. She suggested that retrospective studies be
used to understand treatment responses in biomarker negative populations because like Dr. Temple,
she believed everyone would want to know if this population could benefit as well but it is not a
requirement for biomarker-guided therapies. Drug developers will need to carefully consider these
implications for their clinical trial decisions and it appears that despite emerging recommendations for
targeted therapy development, actual decisions for clinical trial strategies may differ greatly.
Ethical Considerations for Prevalence Thresholds
Several interviewees suggested that with a hypothesis that a biomarker negative population would not
respond to a drug, it would be unethical to (1) expose those patients to drug-related toxicities who
would not benefit and (2) possibly impact the timeframe and effectiveness of another treatment even if
the hypothesis had not yet been validated. Interestingly in speaking with physicians, I found their
viewpoint and comfort with unknown responses to a drug were considerably different. Dr. Flaherty, an
academic medical center specialist oncologist stated that patients were frequently placed on therapies
with an uncertain response outcome (Flaherty 2012). They also recognize the biological complexity of
the biomarkers and even getting 2/3rds of the way to identifying an appropriate treatment is a benefit -
it is not necessary or even feasible to be 100% positive that the patient will respond. Dr. Mansfield did
provide perspective on this discordance. Both the FDA and companies are evaluating the response to a
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drug at a population level where as a group, it may be unethical to include patients on a trial where it is
suspected they will not benefit. Physicians, however, are evaluating this at an individual level and taking
into account the multitude of factors that could be different for this one individual (Mansfield, 2012).
Combination Therapy
The increasing biological complexity, such as with the interactions of multiple aberrations that can occur
in any given pathway, resistance mechanisms or the extent of tumor heterogeneity, suggests that
combination therapies may be required to achieve the desired curative or at least maintenance patient
responses. If there are multiple potential targets in any one tumor, theoretically, diagnostics will still be
needed to understand which targeted therapies are necessary for treatment. More than one
interviewee, however, noted that a companion diagnostic may not be required in a combination setting,
especially as long as there was patient response seen in such a scenario. This could be due to the fact
that the number of challenges increases to an even greater extent in a combination setting. Therapy
regimen design is only one aspect but yet the combination agent, doses, sequence of therapies, duration
of each agent, all must be selected in clinical trials while balancing mechanisms of action and toxicities.
Combining targeted agents has the potential to increase overall benefit to the patient by synergizing the
anti-tumor effect without a complementary increase in toxicities, hopefully improving the therapeutic
window and potentially counteracting primary and secondary resistance shown by both high and
durable responses. A discussion during ASCO's annual meeting this year (and published in its education
book) focused specifically on this idea; combining targeted agents in clinical trials. The above benefits
were listed as opportunities as well as further agents that do not have single agent lethality, which may
be the case for these targeted agents dealing with complex biological pathways. One of the key
challenges was in fact how to use biomarkers to guide treatment. The slow pace of biomarker
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development to support such hypotheses and the lack of standardized designs for clinical trials are key
impediments to combining targeted agents (Mateo, 2012), which is what the interviewees in this study
also mentioned. Further investigation will need to be performed to better understand how to best
capitalize on the impact of stratified therapies in a combination setting.
Areas for Future Research
This study provides interesting insights that actual activities surrounding biomarker guided drug
development still face significant challenges despite now several successful case studies of stratified
medicine (trastuzumab, imatinib, vemurafenib, crizotinib). Several opportunities for future research
that could be undertaken in order to facilitate continued understanding of the factors influencing
targeted drug development decisions. A similar type of qualitative study could be performed with a
wider set of biologically complex drug targets and a more complete set of respondents for each
program. Such a study could be augmented by a quantitative study in which respondents would be
forced to choose levels of prevalence and companion diagnostic performance levels to understand what
decisions would be made in a given scenario.
Modeling could also be performed to understand the interplay between the primary factors of
therapeutic efficacy, prevalence and companion diagnostic performance and given a particular level,
what thresholds would be required for commercial success. A retrospective study on which indications
companies pursued could provide insight on while there may not be theoretical prevalence thresholds
to guide decisions, there may have been certain levels needed to pursue clinical investigation. In a
number of years it would also be interesting to survey the clinical trial protocols of biomarker guided
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therapies and evaluate whether trends or even thresholds emerged as knowledge of complex biological
pathways and drug response increased.
A secondary line of questioning could surround the burgeoning area of companion diagnostics. Given
the limited knowledge of the intricacies of this industry that was found in drug development leaders, it
would be interesting to understand where this information is being pulled from in order to progress a
targeted drug through clinical development. These partnerships have immense challenges as discussed
in the Background section. Further studies could be done to understand the operational strategies,
incentive alignment and factors that contribute to overall diagnostic success. Interestingly, there is
limited data on the adoption patterns of diagnostics and it may be critically important to understand
what factors contribute to companion diagnostic success and what factors also affect the drug adoption
and commercial value as well.
6. Conclusion
This qualitative pilot study found that developers of "pathway-modifying" targeted therapies are not
using common thresholds of prevalence or companion diagnostic performance to guide the biomarker
strategy for clinical trial decisions. Prevalence thresholds for choosing an all-comers versus biomarker-
guided clinical trial strategy varied widely indicating that further investigation and modeling is needed to
understand the implications of biomarker prevalence on clinical trial results. Each program investigated
was planning to use a companion diagnostic, however, specific target performance levels were lacking
for the majority of study respondents. Interestingly, most of the respondents felt that the drug program
would either not move forward or be prioritized without the companion diagnostic, making the
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knowledge gaps even more critical. Conservative biomarker cutoffs, such as complete tumor suppressor
loss, may be an approach to dealing with the technological challenges facing assay validation.
Essentially, as was heard from several respondents, drug activity was the primary outcome of early stage
clinical trials and understanding how best to identify those patients with desired responses was a
secondary objective. This illustrates the juxtaposition where although each drug program faces similar
challenges, in early phase clinical trials there is not a standard trial design. An almost equal number of
trials were using an all-comers or biomarker-guided strategy. Only upon phase 11 trials were the
strategies aligned as biomarker-guided although the results were not statistically significant. Enriching a
phase I trial was an approach that 2/3rds of the respondents were planning to take, suggesting a
movement towards more standardized processes.
With several successes case studies of stratified medicine, especially in oncology, discussions have
yielded several "best practices" that do not in fact represent the actual activities or decisions of drug
developers. Recommendations for developing targeted therapies have begun to emerge and are slowly
being implemented such as using phase I expansion arms to better validate a scientific hypothesis while
hopefully minimizing the disadvantages of using a phase I biomarker selected only population.
Processes to incorporate companion diagnostics into the drug development process have also begun to
take shape in order to anticipate regulatory requirements. The key message here is to initiate a
companion diagnostic as soon as possible and have a potentially commercializable assay available for
pivotal trial testing. Based on this study, for biological complex targets such as "pathway-modifying"
programs (CDK4/6, MDM2, P13KP), the companion diagnostic is a concern but may not be reliable even
once the drug enters clinical trials and even into phase 11 and perhaps greatly threatening the drug's
success.
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Although several drug programs have achieved clinical, regulatory and commercial success, significant
work still needs to be done in order to better align the drug and companion diagnostic development
processes since future programs will experience arguably greater challenges. The challenges
surrounding scientific hypotheses, biomarker validation, clinical trial design, regulatory requirements,
commercial value and ethical considerations all contribute to the significant uncertainty plaguing
targeted therapies and likely leads to the findings of this study. Standards for prevalence and
companion diagnostics thresholds for "pathway-modifying" targeted therapies are not yet established
and the current actual clinical trial decisions made by drug developers do not yet correlate with
recommendations emerging in the literature and stratified medicine community.
Implications
Based on my research findings, I suggest the following implications for drug developers of targeted
oncology therapies when making decisions on biomarker-guided clinical trial strategies:
1. Drug developers are not using common prevalence thresholds to determine whether to pursue
biomarker-guided strategies in early stage clinical trials for "pathway-modifying" targeted therapies.
Further evaluation is needed to understand what prevalence levels are required for efficient clinical
trials and ultimately commercially successful targeted therapies.
2. Biomarker-guided clinical trial strategy decisions are not influenced by companion diagnostic
performance levels as there were no common desired sensitivity or specificity levels. Drug
developers have limited knowledge of the companion diagnostic processes and significant expertise
will need to be gained through partnerships with diagnostic companies, further complicating the
drug development process.
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3. Significant uncertainty and challenges still exist for validating biomarkers due in part to increasing
biological complexity. Processes will need to be developed to support biomarker validation but this
can also only be accomplished through further clinical investigations. Using more phase I expansion
cohorts during clinical trials to test hypotheses may be valuable.
4. Choosing conservative biomarker cutoff values may be a way for drug developers to minimize the
uncertainty and challenges that surround biomarker validation. Initially conservative cutoffs can
help the drug achieve approval but further investigations will be needed to understand how best to
benefit applicable patients.
5. Phase I expansion cohorts are being used to further investigate and confirm scientific hypotheses for
"pathway-modifying" therapies, however, some trials are pursuing biomarker-selected only patient
populations in early-stage clinical trials suggesting that oncology community recommendations are
not being taken into account or ethical considerations are overpowering scientific inquiry.
6. There is potentially a disconnect between drug developers and clinicians in that clinicians are willing
to consider all the factors contributing to the challenge of accurate biomarker detection in
determining which patients may benefit from treatment while some drug developers are more
concerned with eliminating the possibility of exposing patients to toxicities without a therapeutic
benefit.
7. The additional challenges of combining targeted therapies may be causing drug developers to
abandon the use of biomarker-guided strategies in combination settings.
8. The assays to support companion diagnostics, regardless of singular or multi-modality approaches,
are still being investigated even through phase I trials despite insistences that the companion
diagnostic process should begin as early as possible and have a commercializable assay before
entering pivotal/phase Ill trials. The considerable technical challenges of companion diagnostic
development are potentially threatening the success of future stratified targeted therapies.
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